Regulatory information – adjusted fees for pharmacovigilance applications from 18 October 2018
NewsHumanCorporateFeesPharmacovigilance
Pharmacovigilance fees payable to the European Medicines Agency by applicants and marketing authorisation holders increase by 1.7% as of 18 October 2018, to reflect the inflation rate adjustments of 2017.
All applications received by or having a data lock point (DLP) of 17 October 2018 will be charged the current fee and reduction rates. Applications received or having a DLP after that date will be charged the adjusted rates.
Further details of the new fee levels are available in the Commission Delegated Regulation (EU) No 2018/1298 amending Regulation (EU) No 658/2014 and the Explanatory note on pharmacovigilance fees payable to EMA (as of 4 October 2023)